World's largest independent biotech firm to pump $245m into Singapore

Amgen, the world's largest independent biotechnology firm, is setting up its first Asian manufacturing facility in Singapore, the Economic Development Board announced.

The US-based, Fortune 500 company, headquartered in California is expected to invest about US$200 million to build an innovative new facility at the Tuas Biomedical Park.

EDB's director of Biomedical Sciences Kevin Lai said: "Amgen's decision is a strong testament to Singapore's track record in biologics manufacturing. We are proud that the Singapore facility will be Amgen's first major investment in Asia utilising its state-of-the-art technology which will transform the future of biologics industry and making healthcare more affordable."